Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia

• The 309T>G polymorphism in the promoter region of the MDM2gene, known as SNP309, has recently been suggested as an unfavorable prognostic marker in chronic lymphocytic leukemia (CLL) although this has been questioned. To investigate this further, we analyzed the MDM2 SNP309 genotypes in 418 CLL patients and correlated the results with established CLL prognostic factors, time to treatment and overall survival. In this Swedish cohort, no association existed between any particular MDM2 SNP309 genotype, overall survival and time to treatment. Furthermore, no correlation was shown between the MDM2 SNP309 genotypes and Binet stage, IGHV mutational status and recurrent genomic aberrations. In summary, this study argues against the use of the MDM2 SNP309 as a prognostic marker in CLL.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Nyckelord

MDM2 SNP309

Chronic lymphocytic leukemia

Binet stage

IGHV mutational status

Genomic aberrations

Prognostic markers

MEDICINE

MEDICIN

Clinical Genetics

Klinisk genetik

Medicin

Medicine

Oncology

Onkologi

Medical Genetics

Medicinsk genetik

Molekylär genetik

Molecular Genetics

Genomic aberrations

Prognostic markers

status

IGHV mutational

Binet stage

MDM2 SNP309

Chronic lymphocytic leukemia

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)